nootropic comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-06. Numbers and descriptions here follow the published literature rather than marketing material.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic heptapeptide | Stabilized analog of tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form: TKPRPGP |
| Molecular formula | C33H57N11O9 | Monoisotopic mass about 751.9 Da |
| Appearance | White to off-white powder | Typically supplied as lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in common polar solvents |
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Acetosyringone and other phenolic compounds alpha-Hydroxyacetosyringone Catechol Ferulic acid Gallic acid p-Hydroxybenzoic acid Protocatechuic acid Pyrogallic acid Resorcylic acid Sinapinic acid Syringic acid Vanillin
Sulfamethoxazole (SMZ or SMX) is an antibiotic. It is used for bacterial infections such as urinary tract infections, bronchitis, and prostatitis and is effective against both gram negative and positive bacteria such as Escherichia coli and Listeria monocytogenes. Common side effects include nausea, vomiting, loss of appetite, and skin rashes. It is a sulfonamide and bacteriostatic. It resembles a component of folic acid. It prevents folic acid synthesis in the bacteria that must synthesize their own folic acid. Mammalian cells, and some bacteria, do not synthesize but require preformed folic acid (vitamin B9); they are therefore insensitive to sulfamethoxazole. It was introduced to the United States in 1961. It is now mostly used in combination with trimethoprim (abbreviated SMX-TMP). The SMX-TMP combination is on the WHO Model List of Essential medicines as a first-choice treatment for urinary tract infections. Other names include: sulfamethalazole and sulfisomezole.
== Pharmacokinetics == Maximum decrease in blood pressure occurs 4–6 hours after oral dosage. The half-life of methyldopa is 105 minutes. Methyldopa exhibits variable absorption from the gastrointestinal tract. It is metabolized in the liver and intestines and is excreted in urine.
Activities of focus included concentrated weightlifting, change of diet, and the use of creatine and androstenedione. By the start of the 1996 season, Bagwell and Biggio had gained seniority, even if not necessarily by age, within the Astros clubhouse as well as status as superstars. According to sportswriter Dayn Perry, the earliest recorded reference to an Astros version of the nickname "Killer B's" encountered via a Google Search occurred that year. Bagwell enforced accountability and preparation which fostered camaraderie and incorporated all players as instrumental to the success of the team. Thus, the Astros raised their level of play, and a new string of playoff appearances followed. In time, all who entered the Astros gym were greeted with a banner that read: "Bagwell's Gym. Work Hard. Play Hard. Or Leave." On May 7 against Philadelphia, Bagwell reached the 500th RBI of his career with two home runs and four RBI. By hitting his second upper-deck home run at Three Rivers Stadium on May 29 — it travelled 459 feet (140 m) — Bagwell joined longtime Pirate Willie Stargell as the only players to homer twice into the stadium's upper deck. For the month of May, he batted .360 with .740 SLG, 10 home runs, 31 RBI, 22 runs scored, and four stolen bases. He was named NL Player of the Month, his fourth career monthly award. On June 14, Bagwell tied a major league record with four doubles in one game against San Francisco. He played all 162 games that year, batting .315 with a 1.021 OPS, 31 home runs, 120 RBI, 111 runs scored, and 135 walks.
Ketobemidone, sold under the brand name Ketogan (a mixture of ketobemidone and Spasmolytic A29) among others, is a powerful synthetic opioid painkiller. Its effectiveness against pain is in the same range as morphine, and it also has some NMDA-antagonist properties imparted, in part, by its metabolite norketobemidone. This may make it useful for some types of pain that do not respond well to other opioids. It is marketed in Denmark, Iceland, Norway. Until 2024 it was available in, but is now withdrawn in Sweden. It is used for severe pain.
Sources: en.wikipedia.org
The area under the effect curve (AUEC) is an integral of the effect of a drug over time, estimated as a previously-established function of concentration. It was proposed to be used instead of AUC in animal-to-human dose translation, as computer simulation shows that it could cope better with half-life and dosing schedule variations than AUC. This is an example of a PK/PD model, which combines pharmacokinetics and pharmacodynamics. Cmax (pharmacology) Cmean (pharmacology) "Area Under Curve" of the Receiver operating characteristic
==== In aqueous solution ==== Most neptunium coordination complexes known in solution involve the element in the +4, +5, and +6 oxidation states: only a few studies have been done on neptunium(III) and (VII) coordination complexes. For the former, NpX2+ and NpX+2 (X = Cl, Br) were obtained in 1966 in concentrated LiCl and LiBr solutions, respectively: for the latter, 1970 experiments discovered that the NpO3+2 ion could form sulfate complexes in acidic solutions, such as NpO2SO+4 and NpO2(SO4)−2; these were found to have higher stability constants than the neptunyl ion (NpO2+2). A great many complexes for the other neptunium oxidation states are known: the inorganic ligands involved are the halides, iodate, azide, nitride, nitrate, thiocyanate, sulfate, carbonate, chromate, and phosphate. Many organic ligands are known to be able to be used in neptunium coordination complexes: they include acetate, propionate, glycolate, lactate, oxalate, malonate, phthalate, mellitate, and citrate. Analogously to its neighbours, uranium and plutonium, the order of the neptunium ions in terms of complex formation ability is Np4+ > NpO2+2 ≥ Np3+ > NpO+2. (The relative order of the middle two neptunium ions depends on the ligands and solvents used.) The stability sequence for Np(IV), Np(V), and Np(VI) complexes with monovalent inorganic ligands is F− > H2PO−4 > SCN− > NO−3 > Cl− > ClO−4; the order for divalent inorganic ligands is CO2−3 > HPO2−4 > SO2−4. These follow the strengths of the corresponding acids. The divalent ligands are more strongly complexing than the monovalent ones.
Although the totality of the data that have been reviewed provides reassurance, pancreatitis will continue to be considered a risk associated with these drugs until more data are available; both agencies continue to investigate this safety signal." Lawsuits have been filed in which plaintiffs who developed pancreatic cancer claim that DPP-IV inhibitors or incretins had a causative role in the development of their cancers.
The cable sent from NATO headquarters on 11 August 2008 said that "A number of Allies - especially Germany - are parroting Russian points on Georgian culpability for the crisis" and "intelligence releasable to NATO Allies on this point might be a useful tool" to counter these allegations. One cable reported on 14 August: "Merabishvili told us that the escalation of the conflict occurred after the villages of Nuli and Avnevi were destroyed. Since OSCE observers were hunkered down in Tskhinvali, they could not hear the bombing in Avnevi". The cable reported on 15 August that Ainārs Šlesers, Latvian minister of transport, who suggested that Saakashvili was guilty for the war, made money on deals involving Russia. Russian ambassador to Latvia appealed to business interests of Latvian politicians to prevent sanctioning of Russia.
Validation - The first definition indicates confirmation (through the provision of strong, sound, objective evidence) that requirements for a specific intended use or application have been fulfilled. However, within the family of definitions, it is frequently used in a manner synonymous with verification. Verification - often used to indicate a persona or identity has been verified against a database, such as a PIN-protected identify certificate matches a controlled access list.
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.
It was developed in Russia, at the Institute of Molecular Genetics of the Russian Academy of Sciences, during the 1990s. Most published research originates from Russian institutions. Independent international replication remains limited.
Tuftsin is a natural tetrapeptide with the sequence Thr-Lys-Pro-Arg that participates in immune signaling. Selank extends that sequence with Pro-Gly-Pro at the C-terminus. The added residues are linked to greater resistance to enzymatic breakdown.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.